top of page
Search

Novi and Eli Lilly in fierce competition

  • Writer: DrShivago
    DrShivago
  • Apr 1
  • 1 min read

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly

PUBLISHED TUE, MAR 31 20267:39 AM EDTUPDATED TUE, MAR 31 20262:10 PM EDT

SHAREShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email

KEY POINTS

  • Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients pay lower, “predictable” monthly prices. 

  • Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two highest doses of the newly launched pill under the same brand name.

  • Longer subscriptions offer lower monthly pricing, with people expected to save up to $1,200 a year on the injection and as high as $600 a year on the pill.

In this article

Follow your favorite stocksCREATE FREE ACCOUNT

 
 
 

Recent Posts

See All
Oral GLP

Oral GLP-1 drugs are likely to expand the market massively The more disruptive development may actually be oral agents. Many patients are willing to take a pill but reluctant to self-inject indefinite

 
 
 

Comments

bottom of page